Recent Updates — VIVS

Organovo Inc., a wholly-owned subsidiary of VivoSim Labs, entered into a second amendment to its lease for principal executive offices in San Diego. The agreement requires vacating Suite 202 by February 28, 2027, while extending the term for Suite 100 through April 30, 2028. Monthly base rent is adjusted to $43,072.85, with a rental abatement of $21,536.43 per month from March 1, 2027, through June 30, 2027. VivoSim Labs operates in the biotechnology sector, providing simulation and testing services.

At its annual meeting, VivoSim Labs stockholders approved a board authorization to execute a reverse stock split at any ratio between 1-for-5 and 1-for-20 by September 30, 2027. They also authorized the reduction of common stock purchase warrant exercise prices from $9.60 to $0.85 per share and approved the issuance of approximately 4.7 million shares upon their exercise. Additionally, shareholders ratified directors, auditors, executive compensation, and increased equity plan reserves by 3.165 million shares. VivoSim Labs operates in the medical simulation industry.

VivoSim Labs, Inc. received a notice from Nasdaq on August 17, 2026, indicating it failed to maintain the minimum $1 bid price requirement due to its closing stock price over the preceding 30 consecutive business days. The company has an initial compliance period until February 16, 2027, to regain compliance by achieving a closing price of at least $1 for ten consecutive business days. Failure to comply may result in delisting proceedings, though the company retains the option to seek an additional compliance period if it meets other listing standards. To address this deficiency, VivoSim has included a proposal in its preliminary proxy statement for shareholder approval of a reverse stock split with a ratio between 1-for-5 and 1-for-20, subject to Board determination. The filing does not announce a specific effective date or final ratio for the split. VivoSim Labs operates in the biotechnology sector, focusing on developing simulation technologies for drug discovery.

VivoSim Labs announced regained compliance with Nasdaq Listing Rule 5550(b)(1) regarding minimum stockholders' equity of $2.5 million following a $5.0 million milestone payment from Eli Lilly and a $4.0 million financing transaction in July 2026. The company reported preliminary cash on hand of approximately $10.1 million as of August 3, 2026, with common shares outstanding increasing to 13,390,789 due to warrant exercises. Management anticipates over 500% revenue growth in fiscal year 2027 driven by its contract research services using new approach methodologies (NAMs). VivoSim Labs operates as a pharmaceutical and biotechnology services company focused on providing preclinical safety testing of drug candidates using three-dimensional human tissue models.

VivoSim Labs, Inc. received a Nasdaq delisting notice due to failing to meet the $2.5 million minimum stockholders' equity requirement. The company has until September 3, 2026, to submit a compliance plan, though recent capital raises and a $5.0 million milestone payment from Eli Lilly and Company have brought stockholders' equity above the $2.5 million threshold. VivoSim Labs, Inc. is a biotechnology company focused on developing FXR assets.